Shingrix In Recipients of Allogeneic Transplants

Phase 2 Recruiting 55 enrolled University of Colorado, Denver GlaxoSmithKline · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval after transplantation on the immune response and if an additional dose of vaccine is needed to improve the vaccine-induced responses.

Timeline

Start: 2023-10-24
Primary completion: 2028-01-20
Completion: 2030-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E	Vaccine	—	Other

Indications

No indication recorded.